论文部分内容阅读
目的观察丹红注射液对急性冠脉综合征(ACS)患者血清超敏C-反应蛋白(hs-CRP)的影响,探讨其作用机理。方法将86例ACS患者随机分为治疗组和对照组各43例。两组均给予常规治疗,治疗组在此基础上加用丹红注射液治疗2周。在治疗前及治疗2周后分别检测两组血清hs-CRP水平。结果两组治疗前血清hs-CRP水平比较,差异无统计学意义(P>0.05);在治疗后,两组血清hs-CRP水平均较治疗前明显降低(P<0.01),但治疗组血清hs-CRP水平较对照组下降更明显,且与对照组比较有极显著性差异(P<0.01)。结论丹红注射液能降低ACS患者血清hs-CPR水平,抑制动脉粥样斑块内炎症反应。
Objective To observe the effect of Danhong injection on serum hs-CRP in patients with acute coronary syndrome (ACS) and to explore its mechanism. Methods 86 patients with ACS were randomly divided into treatment group and control group, 43 cases each. Both groups were given conventional treatment, the treatment group on this basis with Danhong injection for 2 weeks. Before treatment and after 2 weeks of treatment, serum hs-CRP levels were measured in both groups. Results The serum hs-CRP levels in the two groups before treatment did not differ significantly (P> 0.05). After treatment, the levels of hs-CRP in both groups were significantly lower than those before treatment (P <0.01) hs-CRP levels decreased more significantly than the control group, and compared with the control group had a very significant difference (P <0.01). Conclusion Danhong injection can reduce the level of serum hs-CPR in ACS patients and inhibit the inflammatory reaction in atherosclerotic plaques.